Proposal for a statutory restructuring plan
Mar 31, 2022
Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that the enclosed proposal for a statutory restructuring plan will be submitted to the Danish Maritime and Commercial High Court (the “Court”) and be sent to the Company’s known creditors in accordance with section 11 c of the Danish Insolvency Act. Further, the Court has appointed state-authorized public accountant Søren Søndergaard Jensen as restructuring accountant.
Proposal for a statutory restructuring plan
Proposal for a statutory restructuring plan including appendix 1 4
Read moreUpdated Financial Calendar for 2022
Mar 29, 2022
Orphazyme A/S in restructuring Company announcement No. 14/2022 www. orphazyme. com Company Registration No. 32266355 Copenhagen, Denmark, March 29, 2022 – Orphazyme A/S in restructuring (ORPHA.
Updated Financial Calendar for 2022
Read moreOrphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C
Mar 22, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that, following the receipt of the negative Trend Vote by the Committee for Medicinal Products for Human Use (CHMP) as announced on February 23, 2022 (please see company announcement no. 07/2022), the Company has decided to withdraw its European Marketing Authorisation Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP on the MAA scheduled for later this month.
Orphazyme announces withdrawal of European MAA for arimoclomol for the treatment of NPC
Read moreOrphazyme A/S has filed for voluntary delisting of ADSs
Mar 21, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that following the decision to voluntarily delist the Company’s American Depositary Shares (“ADSs”) representing its ordinary shares from Nasdaq Global Select Market (“Nasdaq Global”) (please see announcement no. 10/2022), the Company has today initiated the delisting and filed a Form 25 with the Securities and Exchange Commission (“SEC”). The delisting is expected to become effective on March 31, 2022. The Company has also filed post-effective amendments to two Registration Statements on Form S-8 and one Registration Statement on Form F-3 previously filed by the Company with the SEC to remove from registration any unsold securities previously registered thereon.
Notice of in court restructuring proceedings of Orphazyme
Read moreNotice of in-court restructuring proceedings of Orphazyme A/S
Mar 18, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that following the Company’s filing of a petition for an in-court restructuring (in Danish rekonstruktion) of Orphazyme on March 10, 2022 (please see company announcement no. 10/2022), the Danish Maritime and Commercial High Court (the “Court”) has commenced the restructuring proceedings of the Company on March 11, 2022 at 7:00 am (CET). The Court has appointed attorney John Sommer Schmidt as restructuring administrator.
Notice of in court restructuring proceedings of Orphazyme
Read moreCommencement of in-court restructuring of Orphazyme A/S
Mar 10, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that, following the receipt of the negative Trend Vote as announced on February 23, 2022 (please see company announcement no. 07/2022), and considering the Company’s financial position, the Board of Directors of the Company has today decided to file a petition for an in-court restructuring of Orphazyme. As a part of the restructuring efforts, the Company will also institute a reduction of approximately 50% of the Company’s current global workforce.
Commencement of in court restructuring of Orphazyme
Read moreUpdated Financial Calender for 2022
Mar 3, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announced an update to the Financial Calendar for 2022. The planned date of the Annual General Meeting is changed to April 29, 2022, and the publication of the Annual Report for 2021 is changed to April 7, 2022.
Updated Financial Calender for 2022 1
Read moreAnders Vadsholt takes over as CEO of Orphazyme
Feb 28, 2022
Company announcement No. 08/2022 www. orphazyme. com Company Registration No. 32266355 Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.
Anders Vadsholt takes over as CEO of Orphazyme
Read moreOrphazyme announces update on regulatory review of arimoclomol in the European Union
Feb 23, 2022
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Orphazyme announces update on regulatory review of arimoclomol in the European Union
Read moreCapital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
Feb 18, 2022
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, announces that the Company has issued new shares in the period from Friday, February 11, 2022 to Thursday, February 17, 2022 as a result of the utilization of the Company’s U.S. At-the-Market Offering Program with Cowen and Company, LLC (“Cowen”). On February 11, 2022, a total of 360,000 ordinary shares of nominally DKK 1 each, represented by American Depositary Shares (“ADSs”), have been issued by the Company and sold in the market by Cowen as the sales agent at market price as determined by the Company’s Board of Directors in accordance with the authorization in article 3.1 of the Company’s Articles of Association.
Read more